Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Jan-Mar;20(1):1-3.
doi: 10.1080/10401230701844802.

Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington's disease

Kevin Duff  1 , Leigh J Beglinger, Margaret E O'Rourke, Peg Nopoulos, Henry L Paulson, Jane S Paulsen
Affiliations

Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington's disease

Kevin Duff et al. Ann Clin Psychiatry. 2008 Jan-Mar.

Abstract

Background: Huntington's disease (HD) is a progressive, neuropsychiatric disorder, and limited reports indicate that risperidone might improve motor and psychiatric functioning for these patients.

Methods: In a retrospective, chart review study to evaluate the effectiveness of risperidone on motor, psychiatric, and cognitive functioning in HD, 17 patients taking risperidone in the course of clinical care and 12 patients not taking any antipsychotic medication were compared across a year.

Results: Patients taking risperidone demonstrated significantly improved psychiatric functioning and motor stabilization, whereas patients not taking risperidone were stable psychiatrically and worsened motorically.

Conclusions: Although controlled clinical trials are clearly needed, these preliminary results support the use of risperidone in patients with HD in treating their psychiatric and possibly motor symptoms.

PubMed Disclaimer

References

    1. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006 Feb 14;66(3):366–372. PubMed PMID: 16476934. - PubMed
    1. Huntington Study Group. Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study. Neurology. 2003 Dec 9;61(11):1551–1556. PubMed PMID: 14663041. - PubMed
    1. Puri BK, Leavitt BR, Hayden MR, Ross CA, Rosenblatt A, Greenamyre JT, Hersch S, Vaddadi KS, Sword A, Horrobin DF, Manku M, Murck H. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology. 2005 Jul 26;65(2):286–292. PubMed PMID: 16043801. - PubMed
    1. van Vugt JP, Siesling S, Vergeer M, van der Velde EA, Roos RA. Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study. J Neurol Neurosurg Psychiatry. 1997 Jul;63(1):35–39. PubMed PMID: 9221965; PubMed Central PMCID: PMC2169648. - PMC - PubMed
    1. Marder K, Zhao H, Meyers RH, Cudkowicz M, Kayson E, Kieburtz K, Orme C, Paulsen J, Penney JB, Siemers E, Shoulson I the Huntington Study Group. Rate of Functional decline in Huntington’s disease. Neurology. 2000 Jan 2;:452–458. - PubMed

MeSH terms

LinkOut - more resources